The U.S. Food and Drug Administration has granted full approval to Eli Lilly’s Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer whose disease has progressed after at least one line of endocrine therapy. The approval, announced September 18, applies to patients whose ESR1 mutation is confirmed using an FDA-authorized test, and arrives just under a year after Inluriyo’s original single-agent approval for the same underlying patient population.
Why ESR1 Mutations Matter in Breast Cancer
ESR1 mutations develop in roughly half of patients with ER-positive, HER2-negative metastatic breast cancer during or after treatment with aromatase inhibitors, a widely used class of hormone-blocking therapies that form a backbone of standard breast cancer treatment. These mutations cause estrogen receptors to become overactive, allowing tumors to keep growing even while a patient remains on hormone-blocking treatment, effectively driving acquired resistance to a therapy that had previously been working. Testing for ESR1 mutations helps oncologists identify which patients whose cancer has progressed on endocrine therapy might benefit from switching to a treatment specifically designed to address that resistance mechanism, rather than continuing a regimen the tumor has already adapted around.
How Inluriyo and Verzenio Work Together
Inluriyo is an oral selective estrogen receptor degrader, or SERD, designed to bind to and break down the mutated estrogen receptors responsible for driving tumor growth in ESR1-mutated cancer. Verzenio, by contrast, is a CDK4/6 inhibitor, a drug class that blocks proteins tumor cells rely on to divide and multiply. Combining the two gives patients a treatment approach that targets two distinct biological drivers of ER-positive breast cancer simultaneously, rather than relying on a single mechanism alone. Notably, the combination is entirely oral, sparing patients the infusion visits that some other advanced breast cancer treatments require.
The “Switch at Progression” Strategy
A key element of how this approval is structured involves timing. Rather than starting both drugs together from the outset, the approved regimen calls for switching a patient from Inluriyo alone to the Inluriyo-Verzenio combination specifically at the point of clinical progression.
“This evidence-based practice spares early exposure to additional adverse events and mitigates avoidable costs to the healthcare system.”
— Jacob Van Naarden, EVP and President, Lilly Oncology
The Clinical Evidence Behind the Approval
The approval rests on data from the Phase 3 EMBER-3 trial, which enrolled 874 patients with ER-positive, HER2-negative advanced breast cancer overall, with a specific ESR1-mutated subgroup of 159 patients central to this approval, 92 who received Inluriyo alone and 67 who received Inluriyo combined with Verzenio, all following prior treatment with an aromatase inhibitor, with or without a CDK4/6 inhibitor, in either the adjuvant or metastatic treatment setting.
Among that ESR1-mutated group, the Inluriyo-Verzenio combination doubled median progression-free survival compared with Inluriyo alone, 11.1 months versus 5.5 months, with a hazard ratio of 0.53. It’s worth noting what the data doesn’t yet show: overall survival results remained immature at the time of this interim analysis, with only 35 percent of expected deaths reported among ESR1-mutated patients so far, meaning the approval rests on a clear and statistically significant progression-free survival benefit rather than confirmed evidence the combination extends how long patients live overall, a distinction the FDA’s own review specifically noted.
Safety Considerations
Both drugs carry established safety profiles that patients and physicians will need to weigh. Inluriyo’s prescribing information includes a warning for embryo-fetal toxicity. Verzenio’s label carries warnings for diarrhea, neutropenia, interstitial lung disease or pneumonitis, liver toxicity, venous thromboembolism, and embryo-fetal toxicity as well. Lilly has emphasized that the combination doesn’t introduce new monitoring requirements beyond what’s already established for each drug individually, framing the regimen’s tolerability profile as one of its practical advantages for patients already familiar with either medication.
From First Approval to Established Standard
Inluriyo’s trajectory over the past year illustrates how quickly this treatment has moved from new approval to standard practice. The FDA first approved Inluriyo as a single agent in September 2025 for the same ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer population. According to Lilly, Inluriyo has since become the leading treatment option for this patient group, now reaching more than half of all patients starting an oral SERD, a notable market position for a drug not yet a year past its original approval. The FDA also approved the Guardant360 CDx assay as a companion diagnostic alongside this week’s decision, giving oncologists an FDA-authorized test specifically validated to identify the ESR1 mutations this combination is designed to treat.
What Comes Next
For patients whose ER-positive, HER2-negative breast cancer has progressed on endocrine therapy and carries an ESR1 mutation, this approval formalizes a treatment sequence many oncologists were likely already anticipating given Inluriyo’s rapid uptake since last year’s initial approval. Longer-term survival data, still maturing as more patients are followed over time, will offer a fuller picture of the combination’s benefit beyond the progression-free survival advantage this approval is built on.
This article is for general informational purposes and does not constitute medical advice. Patients with metastatic breast cancer should discuss treatment options with their oncologist.